Aimmune Therapeutics Presents New PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital Meeting
Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today presented results from longitudinal analyses evaluating immunological outcomes of long-term daily oral immunotherapy (OIT) with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in patients with peanut allergy (PA) for up to 6 years, as well as new data on the utility benefits for Quality of Life (QoL) between pre- and post-OIT health states in children and adolescents with PA who received PALFORZIA and their caregivers in the United Kingdom (U.K.). The data will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Pediatric Allergy and Asthma Meeting (PAAM) Digital Event, November 12-13, 2021.
PALFORZIA was approved as an oral immunotherapy (OIT) for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy on January 31, 2020 by the U.S. Food and Drug Administration (FDA), on December 17, 2020 by the European Commission (EC), on April 7, 2021 by the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and on May 4, 2021 by Swissmedic. Use of PALFORZIA may be continued in patients 18 years of age and older. PALFORZIA is not indicated for the emergency treatment of allergic reactions, including anaphylaxis and must always be used in conjunction with a peanut-avoidant diet.
Please see U.S. Important Safety Information below and the full Prescribing Information, including Boxed WARNING, and Medication Guide at www.PALFORZIA.com.
“We have followed more than 650 participants from PALFORZIA clinical trials, in an uncontrolled, open-label extension study, to continue evaluating the long-term effects of PALFORZIA treatment on certain immunological parameters,” said Mohamed Yassine, MD, SVP Global Medical Affairs at Aimmune. “Now, we are proud to share these data of up to 6 years, that suggest continued immunomodulation in PA patients.”
Data presented at the meeting suggest that continued long-term treatment (median treatment duration at the time of the data analysis was 3.21 years, with a maximum duration of 6 years) with PALFORZIA induced long-term immunomodulation, indicating a continued shift away from pretreatment sensitivity to peanut. Key highlights from this data presentation include:
- Median Peanut-Specific IgE levels (psIgE) declined initially in Year 2 from baseline, further lowering with continued treatment over time.
- The median Peanut-Specific IgG4 levels (psIgG4) increased to a peak around Years 2 and 3 from baseline.
- Additionally, median peanut Skin Prick Test (SPT) decreased over time hitting its lowest at Year 5 and plateauing in Year 6.
- Results indicate that median Peanut-Specific IgE to Peanut-Specific IgG4 Ratio (psIgE/psIgG4) declined substantially in Year 1 from baseline and remained lower up to Year 6.
Additionally, results from a cross-sectional, observational study using different data collection methods, conducted in the U.K., provided the first-ever estimates of QoL utility measures for patients and caregivers across different health states relating to OIT in PA. The data showed a gain in utility related to QoL among patients treated with PALFORZIA and their caregivers between untreated PA and post-treated PA OIT health states.
“We know there is a significant daily burden for both patients and caregivers living with peanut allergy, so I’m hopeful to see these new data that indicate a gain in utility measures for QoL after PA OIT treatment with PALFORZIA,” said George du Toit, pediatric allergist, U.K. and an investigator in PALFORZIA clinical trials.
The following abstracts are now available for on-demand viewing on the PAAM scientific program website:
- Poster #P17: Nilsson, C, et al. “Immunological Outcomes of Daily Oral Immunotherapy for Peanut Allergy in Children and Adolescents: Longitudinal Analyses Up to 6 Years.”
- Poster #P20: Gallop, K, et al. “Exploring health-related quality of life burden in peanut allergy and the potential benefit of oral immunotherapy.”
PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 4 through 17 years. Up-Dosing and Maintenance may be continued in patients 4 years of age and older.
PALFORZIA is to be used in conjunction with a peanut-avoidant diet.
Limitations of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis.
IMPORTANT SAFETY INFORMATION
PALFORZIA can cause anaphylaxis, which may be life threatening and can occur at any time during PALFORZIA therapy.
Prescribe injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
Do not administer PALFORZIA to patients with uncontrolled asthma.
Dose modifications may be necessary following an anaphylactic reaction.
Observe patients during and after administration of the Initial Dose Escalation and the first dose of each Up-Dosing level, for at least 60 minutes.
In the US, PALFORZIA is available only through a restricted program called the PALFORZIA REMS.
PALFORZIA is contraindicated in patients with uncontrolled asthma, or with a history of eosinophilic esophagitis and other eosinophilic gastrointestinal disease.
WARNINGS AND PRECAUTIONS
PALFORZIA can cause anaphylaxis, which may be life threatening. In the US, PALFORZIA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the PALFORZIA REMS because of the risk of anaphylaxis. Only prescribers, healthcare settings, pharmacies, and patients certified and enrolled in the REMS Program can prescribe, receive, dispense or administer PALFORZIA.
Anaphylaxis has been reported during all phases of PALFORZIA dosing, including Maintenance and in subjects who have undergone recommended Up-Dosing and dose modification procedures.
Do not initiate PALFORZIA treatment in a patient who has had severe or life-threatening anaphylaxis within the previous 60 days. PALFORZIA may not be suitable for patients with certain medical conditions that may reduce the ability to survive anaphylaxis, including but not limited to markedly compromised lung function, severe mast cell disorder, or cardiovascular disease. In addition, PALFORZIA may not be suitable for patients taking medications that can inhibit or potentiate the effects of epinephrine.
All Initial Dose Escalation doses and the first dose of each Up-Dosing level must be administered in a certified health care setting.
Patients may be more likely to experience allergic reactions following PALFORZIA administration in the presence of cofactors such as exercise, hot water exposure, intercurrent illness (e.g., viral infection), or fasting. Other potential cofactors may include menstruation, sleep deprivation, nonsteroidal anti-inflammatory drug use, or uncontrolled asthma. Patients should be proactively counseled about the potential for the increased risk of anaphylaxis in the presence of these cofactors. If possible, adjust the time of dosing to avoid these cofactors. If it is not possible to avoid these cofactors, consider withholding PALFORZIA temporarily.
Uncontrolled asthma is a risk factor for a serious outcome, including death, in anaphylaxis. Ensure patients with asthma have their asthma under control prior to initiation of PALFORZIA.
PALFORZIA should be temporarily withheld if the patient is experiencing an acute asthma exacerbation. Following resolution of the exacerbation, resumption of PALFORZIA should be undertaken cautiously. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of PALFORZIA.
Eosinophilic Gastrointestinal Disease
Discontinue PALFORZIA and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastrointestinal symptoms, including dysphagia, vomiting, nausea, gastroesophageal reflux, chest pain, or abdominal pain.
Gastrointestinal Adverse Reactions
Gastrointestinal adverse reactions were commonly reported in PALFORZIA-treated subjects, and dose modification should be considered for patients who report these reactions. For severe or persistent gastrointestinal symptoms consider a diagnosis of eosinophilic esophagitis.
The most common adverse events reported in subjects treated with PALFORZIA (incidence ≥ 5% and ≥ 5% than placebo) are abdominal pain, vomiting, nausea, oral pruritus, oral paresthesia, throat irritation, cough, rhinorrhea, sneezing, throat tightness, wheezing, dyspnea, pruritus, urticaria, anaphylactic reaction, and ear pruritus.
Please see full Prescribing Information, including Boxed WARNING, and Medication Guide at www.PALFORZIA.com.
For more information about PALFORZIA, please call 1-844-PALFORZ (1-844-725-3679) or visit www.PALFORZIA.com.
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, including gastrointestinal conditions. Aimmune has one FDA- and EU-approved medicine for peanut allergy and other investigational therapies in development. For more information, please visit www.aimmune.com.
About Nestlé Health Science
Nestlé Health Science (NHSc), a wholly owned subsidiary of Nestlé, is a globally recognized leader in the field of nutritional science. At NHSc we are committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. We offer an extensive consumer health portfolio of industry-leading medical nutrition, consumer and vitamins, minerals and supplements (VMS) brands that are science-based solutions covering all facets of health from prevention to maintenance, all the way through to treatment. NHSc is redefining the way we approach the management of health in several key areas such as pediatric health, allergy, acute care, oncology, metabolic health, healthy aging, gastrointestinal health, and inborn errors of metabolism. Headquartered in Switzerland, NHSc employs over 5,000 people around the world who are committed to making a difference in people's lives, for a healthier today and tomorrow. www.nestlehealthscience.com.
PALFORZIA®, AIMMUNE® and AIMMUNE THERAPEUTICS® are registered trademarks of Aimmune Therapeutics, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wemade Holds Spectacular Event to Celebrate 100 Days Since Global Launch of MIR430.11.2021 05:34:00 EET | Press release
Wemade’s masterpiece mobile MMORPG ‘MIR4’ will hold a spectacular event starting on November 30th, to celebrate the 100th day of its global release. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005798/en/ Wemade’s masterpiece mobile MMORPG ‘MIR4’ holds a spectacular event starting on November 30th, to celebrate the 100th day of its global release. It will be held for two weeks and special rewards will be given including Divine Dragon’s Blessing, Enhancement Stones, Summoning Tickets, and a special box containing various materials. While hunting monsters on the Mir continent, players can obtain Dragon Fruits. In addition, Wayfarer Travel tickets will be updated that allow for transfers to a different server. New Spirits will also be updated including Bloodtip Drago, a legendary-grade fire element Spirit, and Leocrat Khun, an epic-grade earth element Spirit. To commemorate the release of new spirits, a Spirit Special S
LabGenius Appoints Dr. Gino Van Heeke as Chief Scientific Officer30.11.2021 03:00:00 EET | Press release
LabGenius, the machine learning (ML)-driven protein engineering company, today announced the appointment of Gino Van Heeke Ph.D. as Chief Scientific Officer (CSO). In this role, Gino will leverage his wealth of drug discovery and development experience to direct LabGenius’ scientific strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005436/en/ Dr. Gino Van Heeke Appointed as LabGenius' CSO (Photo: Business Wire) “I’m extremely pleased to welcome Gino to the company as CSO,” said Dr. James Field, Founder and CEO of LabGenius. “Gino is an accomplished scientific leader with an impressive track record of successfully advancing drug candidates into pre-clinical and clinical development.” Gino joins LabGenius from Engitix Therapeutics, where, as CSO, he established a portfolio of projects and initiated the company’s first drug discovery campaign. Before this, Gino was Senior Director, Discovery and Early Development
InVeris Training Solutions Unveils SRCE™ – a Revolutionary, Augmented Reality Training System29.11.2021 22:00:00 EET | Press release
InVeris Training Solutions, the leading provider of integrated live-fire and virtual weapons training systems for military, law enforcement agencies and commercial shooting ranges, today unveils SRCE™ (See, Rehearse, Collectively Experience or "Source"), a groundbreaking, augmented reality-based, untethered weapons training simulator. InVeris Training Solutions provides the most advanced augmented reality technology available in a military and law enforcement training simulator, a feat previously thought to be years away by many in the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005628/en/ SRCE is the only untethered AR training solution on the market—allowing up to 4 participants to train with simulated weapons and tactical gear. (Photo: Business Wire) "Augmented reality delivers the best of the virtual and real worlds in a way that's fully lifelike, seamless, customizable and economical," said InVeris CE
Verimatrix Launches Streamkeeper To Offer Industry’s First Battle-Ready Cybersecurity Solution Engineered to Hunt Down and Take Out Video Piracy29.11.2021 19:45:00 EET | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced the launch of its new Verimatrix StreamkeeperSM solution, a cybersecurity and anti-piracy gamechanger for the media & entertainment industry. Streamkeeper empowers customers to hunt down and take out OTT pirates who steal content such as live sports and premium movie as they are distributed from the source to the endpoint (mobile app/user level). The solution includes Verimatrix's all-new CounterspySM technology -- the autonomous injection of an anti-piracy and app protection security agent that utilizes the company’s proprietary zero code technology which allows customers to add deep, defensive countermeasures, plus monitor their clients without the hassle of a huge integration effort. Integration efforts have also been reduced dramatically, from months to minutes, accompanying numerous operator benefits ranging from a reducti
Introducing ThreatConnect 6.4 - Improving Threat Intelligence Processes and SOC Metrics29.11.2021 19:31:00 EET | Press release
ThreatConnect Inc.®, the leader in enabling a risk led and intelligence-driven security is announcing ThreatConnect 6.4, which introduces new capabilities that allow security operations and cyber threat intelligence (CTI) analysts to get useful context faster during investigations and to better measure team efficiencies. ThreatConnect combines its Threat Intelligence Platform (TIP) and Security Orchestration and Automation platform (SOAR), creating a continuous feedback loop that helps make Intelligence-Driven Operations a reality. This latest product release builds upon the foundation of Intelligence-Driven Operations, empowering the workflow of threat intelligence and security operations teams individually and together. The 6.4 release helps CTI and security operations center (SOC) teams get more context quickly, enabling faster investigations for both. CTI teams are enabled to more easily build and maintain a dynamic threat library, while updated dashboards allow SOC and IR leaders
ESI Group Unveils Its New Leadership Team29.11.2021 19:00:00 EET | Press release
Regulatory News: ESI Group (ISIN Code: FR0004110310, Symbol: ESI) (Paris:ESI) announces today the completion of its new leadership team from seasoned professionals from the current organization and the appointment of Ajit Gokhale as Executive Vice-president Engineering. Cristel de Rouvray, Chief Executive Officer of ESI Group says: "With the release of our “OneESI 2024 – Focus to Grow” plan two months ago, we are engaged in a profound transformation. To lead our Group and this transformational effort, I can count on the full support of my new Leadership Team which is composed of nine impressive, complementary and highly experienced individuals. I’m also proud to welcome in our team Ajit Gokhale who will play a key role in our organization and more specifically in our software engineering strategy and execution. Together, we are entirely committed to bring our company to the next level and to transform it as one of the key leading software partners for industry.” Creation of a new leade
Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients29.11.2021 17:00:00 EET | Press release
Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases, has selected AWS as its preferred cloud provider. Innovating on AWS and with the help of AWS experts and partners in healthcare and life sciences, Gilead provides its data scientists with the latest advances in machine learning and analytics. These capabilities fuel data-driven decision making across the organization—from biomarker discovery through manufacturing and clinical trial recruitment—and deliver insights that can help Gilead refine its drug pipeline. The company also relies on AWS to host all workloads for its enterprise resource planning (ERP) transformation project to implement SAP S/4HANA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005047/en/ “With AWS as our pre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom